{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-010191","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.685618+00:00","generated_at":"2026-05-24T02:00:13.066111+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reviva reports FY2024 net loss $29.9M, cash $13.5M; positive OLE data sustained","bullets":["Net loss $29.9M ($0.90/shr) vs $39.3M ($1.65/shr) in 2023; cash $13.5M at Dec 31, 2024 vs $23.4M.","OLE trial: pooled PANSS total score decreased 18.6 points (p≤0.0001) at 1 year; well tolerated with no single side effect >5%.","Registrational Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia expected to initiate mid-2025.","Full OLE data including vocal and blood biomarkers due Q2 2025; NDA submission targeted Q4 2026.","Completed public follow-on offering with gross proceeds of ~$18.0M in December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-010191","json":"https://secwatch.observer/filing/0001437749-25-010191.json","markdown":"https://secwatch.observer/filing/0001437749-25-010191.md","text":"https://secwatch.observer/filing/0001437749-25-010191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/0001437749-25-010191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/rvph20250325_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:00:13.066111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}